Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant or stably-transformed bacterium encoding one or...
Patent
1981-10-28
1983-09-06
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant or stably-transformed bacterium encoding one or...
A61K 3119
Patent
active
044029799
ABSTRACT:
This invention relates to ophthalmic preparations which include 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid or ophthalmologically acceptable salts thereof as the active entity for reducing or controlling inflammation of the eye.
REFERENCES:
patent: 3609184 (1971-09-01), Miyai et al.
patent: 3654349 (1972-04-01), Shen et al.
patent: 3766259 (1973-10-01), Sletzinger et al.
patent: 3888902 (1975-06-01), Shen et al.
Chem. Abst. 85, 87027(r) (1976)--Hucker et al.
Chem. Abst. 86, 183,227(x) (1977)--Duggan et al.
Chem. Abst. 91, 83,391(f) (1979)--Maki et al.
Chem. Abst. 91, 83,392(g) (1979)--Kurachi et al.
Intraocular Lens Symposium--Mar. 25-29 (1980) "Preliminary Report of Clinical Sucess of Topical Sulindac in Treatment of Clinical CME".
Conquet Philippe
Le Douarec Jean-Claude
Shen Tsung-Ying
Merck & Co., Inc. & Laboratories
Merck Sharp & Dohme-Chibret
Monaco Mario A.
Nicholson William H.
Riedl Edmunde D.
LandOfFree
Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenz does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenz, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenz will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1592328